medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2018, Number 2

<< Back

Bol Clin Hosp Infant Edo Son 2018; 35 (2)

BCGosis and Chronic Granulomatous Disease. Clinical case report

Quero-Hernández A, Velasco-Santiago MM, Reyes-Gómez U, Reyes-Hernández KL, Quero-Estrada A

Language: Spanish
References: 18
Page: 124-131
PDF size: 270.16 Kb.


ABSTRACT

Introduction. The application of BCG is safe and effective; however complications can occur such as BCGosis, entity that can have a fatal course. The objective is to present a case of chronic granulomatous disease (CGE) that complicated with BCGosis.
Clinical case. Female patient 9 months of age with induration and ulceration of the right deltoid region, in place of application of BCG, ipsilateral submaxillary adenopathy and intermittent fever, fluid evacuations and generalized tonic-clonic seizures. The dihydrorhodamine-123 test was positive.
Discussion. The complications disseminated by BCG in patients with EGC are from 75 to 90%, in lower frequency to bone marrow (14%). The recurrence of the disseminated disease is 27% and the death can be up to 18%. Therefore, severe adverse reactions of BCG should make EGC suspect and, on the other hand, its application is contraindicated in these patients.
Conclusion. The BCGosis, is a systemic complication by the vaccine, when it is likely that the patient will have some severe immunodeficiency; the EGC is the most common. It has a high risk of mortality and the antituberculosis treatment associated with interferon γ has given good results.


REFERENCES

  1. Kourime M, Akpalu EN, Ouair H, Jeddane L, Benhsaien I, Ailal F et al. BCGitis/BCGosis in children: diagnosis, classification and exploration. Arch Pediatr, 2016; 23 (7): 754-9.

  2. Toida I, Nakata S. Severe adverse reactions after vaccination with Japanese BCG vaccine: a review. Kekkaku, 2007; 82 (11): 809-24.

  3. Cristiane de Jesus Nunes Santos, Sergio D. Rosenzwieg. Bacille Calmette-Guerin complications in Newly described primary immunodeficiency diseases: 2010- 2017. Front Immunol, 2018; 9: 1423. doi:10.3389/fimmu. 2018.01423.

  4. Sellami K, Amouri M, Kmiha S, Bahloul E, Aloulou H, Sfaihi L. Adverse reactions due to the Bacillus Calmette- Guerin vaccine: twenty tunisian cases. Indian J Dermatol, 2018; 63 (1): 62-65.

  5. Espinoza DG, Butte BK, Palma PV, Norambuena RX, Quezada LA. Enfermedad granulomotasa crónica: tres casos clínicos con diferentes formas de presentación. Rev Chil Pediatr, 2015; 86 (2): 112-116.

  6. Arnold DE, Heimall JR. A review of Chronic Granulomatous Disease. AdvTher, 2017; 34: 2543-2557.

  7. Bortoletto P, Lyman K, Camacho A, Fricchione M, Khanolkar A, Katz ZB. Chronic granumolatous disease. Pediatr Infect Dis J, 2015; 34 (10): 1110-1114.

  8. Medrano E´vers A, Morales Hernández AE, Valencia López R, Hernández Salcedo DR. Enfermedad granulomatosa crónica. Med Int Mex, 2017; 33 (3): 407-414.

  9. Baehner LR, Boxer AL, Davis J. The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood, 1976; 48 (2): 309-313.

  10. Rojas J, Álvarez Álvarez J, Montoya Giraldo J, Trujillo Vargas C. Validación de la técnica de dihidrorodamina 1,2,3 para el diagnóstico de la enfermedad granulomatosa crónica en Colombia. Inmunología, 2014; 4 (33): 71-80.

  11. Blancas Galicia L, Espinoza Padilla S, Espinoza Rosales F. 1,2,3 dihidrorodamina, una técnica accesible y útil para la detección de pacientes y portadoras de enfermedad granulomatosa crónica. Experiencia en el Instituto Nacional de Pediatría. Alergia Inmunol Pediátr, 2013; 22 (3): 96-100.

  12. Strickler PA, BOza CA, González MB, Márquez MG, Bustamante J. Infección diseminada por BCG en la Región de los Lagos, Chile: reporte de cinco casos clínicos. Rev Chil Enfer Respir, 2009; 25: 29-38.

  13. Lleras de Torres A, Villalobos H, Alirio Torres A, Bernardoni C, Torres C. Adenitis por BCG en niños con síndrome de inmunodeficiencia adquirida. Dertamol Venez, 2011; 49 (1): 43-47.

  14. Marciano B, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in SCID patients: complications, risks and vaccination policies. J Allergy ClinImmunol, 2014; 133 (34): 1134-1141.

  15. Conti F, Lugo Reyes SO, Blancas Galicia L, He J, Aksu G, Borges de Oliveira E, et al. Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases. J Allergy ClinImmunol, 2016; 138 (1): 241-248.

  16. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/ centers Disease Control and Prevention/Infectious Diseases Society of American Clinical Practice Guidelines: treatment of drug-Susceptible Tuberculosis. Clin Infect Dis, ATS/CDC/IDSA Clinical Practice Guidelines for Drug-Susceptible TB, 2016; 1-49.

  17. Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. Plos One, 2013; 8: e63840.

  18. Ying W, Sun J, Liu D, Hui X, Yu Y, Wan J, et al. Clinical characteristics and Immunogenetics of BCGosis/ BCGitis en Chinese Children: A 6 year Follow-Up. Plos ONE, 2014; 9 (4): 1-6: e94485. doi: 10.1371/journal. pone.0094485.




2020     |     www.medigraphic.com